Loomis, Sayles & Company
DRNA

Loomis, Sayles & Company’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Loomis, Sayles & Company’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,560,057
Closed -$58.2M – 950
2021
Q2 		$58.2M Sell
1,560,057
-31,511
-2% -$966K 0.07% 124
2021
Q1 		$40.7M Buy
1,591,568
+220,296
+16% +$5.63M 0.05% 186
2020
Q4 		$30.2M Buy
1,371,272
+312,817
+30% +$6.89M 0.04% 204
2020
Q3 		$19M Buy
1,058,455
+333,452
+46% +$6.9M 0.03% 243
2020
Q2 		$18.4M Buy
+725,003
New +$15.6M 0.03% 229

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Loomis, Sayles & Company's DRNA Position: Q3 2021 in Review

Loomis, Sayles & Company sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 1,560,057 shares — an estimated $58.2M sold.

Loomis, Sayles & Company first reported a position in DRNA in Q2 2020 and held it in 5 quarters. The position peaked at $58.2M in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

  • Loomis, Sayles & Company reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Loomis, Sayles & Company sold 1,560,057 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $58.2M.
  • Loomis, Sayles & Company first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2020 and held it in 5 quarters.
  • Loomis, Sayles & Company's Dicerna Pharmaceuticals, Inc. position peaked at $58.2M in Q2 2021.
  • 173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Loomis, Sayles & Company's 13F filing for Q3 2021, filed 12 Nov 2021.